SCDAA 46th Annual National Convention has ended

Create Your Own Event

SCDAA 46th Annual National Convention

Celebrating Diversity Within the Sickle Cell Community: Commitment, Innovation, Practice

Latasha Lee

Washington D.C. Metro Area

9:15am

Opening Ceremony: Celebrating Diversity Within the Sickle Cell Community. Meet the New National Child Ambassador Constellation A

10:30am

Plenary Session I Community Based Organization Highlights Constellation AB Treatment Demonstration Update Constellation A

11:00am

Newborn Screening Grant Update Constellation A

11:30am

PCORI Grant Update Constellation A

12:00pm

Hemolytic Anemia in Sickle Cell Disease: What is it and Why Does it Matter? Constellation AB

1:15pm

Developing My Healthcare Passport Frederick/Columbia

1:45pm

Chronic Pain Constellation D

2:15pm

Transplantation Updates Constellation D

2:45pm

Chronic Organ Damage Frederick/Columbia

3:30pm

PLENARY II Clinical Trial Update Constellation A

7:00pm

Chairman's Reception and Generation S " Rock the Block Event " Piesces

9:30am

Charles F. Whitten, MD Memorial Lecture Constellation A

12:00pm

Finding your Voice between the Patient and Caregiver Baltimore/ Annapolis

1:30pm

Lonzie Lee Jones Patient Advocacy Symposium Constellation A

3:15pm

Effect Of Long Term Treatment With Sc411 On Sickle Cell Crisis Rate In Children With Sickle Cell Disease Constellation C Patient and Caregiver Perspectives on Areas of Burden In Sickle Cell Disease Management Baltimore/ Annapolis

3:30pm

Compassionate-Use Voxelotor (GBT440) For Up To 2 Years In Patients With Severe Sickle Cell Disease And Life-Threatening Comorbidities Constellation C The Opioid Epidemic And CDC Guidelines: A Case Of An Unfortunate Consequences Paved By Good Intentions Constellation D

3:45pm

Crizanlizumab 5.0 Mg/Kg Increased the Time to First On-Treatment Sickel Cell Pain Crisis (SCPC) and the Likelihood of not Experiencing SCPC While on Treatment: Subgroup Analyses of the Phase 2 Sustain Study Constellation C

4:00pm

Parent and Youth Barriers to Hydroxyurea Adherence in Adolescents with Sickle Cell Disease Constellation C

4:30pm

Crizanlizumab Treatment is Not Asoociated with the Development of Proteinuria and Hematuria in Patients with Sickle Cell Disease: Sustain Study Safety Analysis Constellation C

4:45pm

Genome Editing to Fix the Sickle Cell Disease Causing Variant in Sickle Cell Patient Hematopoietic Stem Cells Constellation C

5:15pm

The Clinical-Stage SGC Stimulator Olinciguat Prevents Increase Of Plasma Biomarkers Of Intravascular Inflammation And Suppresses Leukocyte-Endothelial Interactions In Tnfa-Treated Mice Constellation C

8:30am

Pravastatin-Mediated Modulation Of Sickle Red Cell Adhesion Using Mouse Endothelial Cells In Vitro Constellation B

8:45am

The Strong-SCD Trial: A Phase 2 Study Ofolinciguat (IW-1701), A Stimulator Of Soluble Guanylate Cyclase (sGC) Inpatients With Sickle Cell Disease (SCD) Constellation B

9:00am

SC411 For Treatment Of Children With Sickle Cell Disease: A Phase 2, Randomized, Double-Blind, Dose-Finding, Placebo-Controlled, Parallel-Group, Multi-Center Study (Scot Trial) Constellation B

9:15am

Clinical Development Of Rivipansel (GMI-1070) For The Treatment Of Acute Vaso-Occlusive Crisis In Sickle Cell Disease Constellation B

9:30am

A Systematic Literature Review Of Patient-Reported Outcome Instruments Used In Sickle Cell Disease Constellation B

10:00am

Gene Therapy for Sickle Cell Disease: Fact or Fiction? Constellation CD

10:30am

Clarice D. Reid, MD Lecture – Global Strategies for Sickle Cell Disease Constellation CD

11:00am

National Partner Updates Constellation CD